American Brain Foundation’s Cure One, Cure Many Award in Neuroinflammation: Breakthrough Grants

The American Brain Foundation’s Cure One, Cure Many Award in Neuroinflammation: Breakthrough Grants aims to revolutionize brain health through innovative research into neuroinflammation. This multimillion-dollar initiative supports high-risk, high-reward projects, funding interdisciplinary teams focused on developing new biomarkers and therapeutic targets. With grants of up to $2 million, the program encourages collaboration across institutions to address conditions affecting a significant portion of the global population.

Since 1992, the American Brain Foundation (ABF) has been investing in research to defeat brain diseases and disorders.
We invest in research of the whole brain and all neurologic disorders knowing they are interconnected. This holistic, innovative approach allows us to build bridges between diseases and break new ground in research and application.
We understand that when we cure one brain disease, we will cure many.
American Brain Foundation’s Cure One, Cure Many Award in Neuroinflammation
The 2025 Cure One, Cure Many Award in Neuroinflammation is a groundbreaking, multimillion-dollar research initiative focused on better understanding neuroinflammation’s role in brain disease, and promises to transform the future of brain health. It will be carried out through two types of grants, one of which is the Breakthrough Grants.
The Cure One, Cure Many Award in Neuroinflammation: Breakthrough Grants support high-risk, high-reward translational research with a focus on clinical impact.
ABF is awarding two Breakthrough Grants of up to US $2 million each (up to $1 million per year for two years). These grants are designed to support interdisciplinary teams investigating novel neuroinflammation mechanisms and the potential development of new biomarkers, therapeutic targets, or technologies. Teams must include members from at least three institutions and ensure that projects bridge multiple disciplines.Up to 15% of the total grant may be used towards indirect costs.
Insights into neuroinflammation’s role in brain health will allow us to more precisely target diseases as different as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, ALS, stroke, brain tumor, epilepsy, migraine, chronic pain, myopathy and neuropathy, traumatic brain injury, schizophrenia, autism and COVID-19-associated brain disease. Together, these diseases affect 60% of the U.S. population and at least 3 billion people worldwide.

Eligibility

Applications may be submitted by basic, translational, or clinical investigators from:U.S. and international public and private non-profit entities, such as universities, colleges, hospitals, and laboratories.U.S. and international biotechnology/pharmaceutical companies, or other publicly or privately held for-profit entities.The principal investigator should hold an MD, PhD, or equivalent terminal clinical degree.

Ineligibility

Applicants may not submit applications for both a Breakthrough Grant and a Catalyst Grant.